2028 Competition Healthcare 
European Pharmaceutical Review
OCTOBER 10, 2024
A draft joint EU network strategy to 2028 has been published by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). The overarching theme of our updated strategy to 2028 is that of change – rapid, somewhat unpredictable but nonetheless full of promise.
World of DTC Marketing
MARCH 17, 2021
A great example of pharma’s profiteering is biosimilar drugs which cost a lot and add billions of dollars to healthcare costs. Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medico Reach
OCTOBER 17, 2022
What really matters are the orthopedic medical device trends that are already shaping the healthcare industry. Advancements in medical technology will always be a favorite topic of discussion when analyzing the healthcare sector. million by 2028. Healthcare executives are also looking into AR spinal surgical systems.
PM360
SEPTEMBER 21, 2023
As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. They do not have biosimilar or generic competition available in the market.
Pharmaceutical Technology
JANUARY 30, 2023
These are forecast to generate $264 billion in sales between 2021 and 2028. Comirnaty, which was first approved in the UK by an Emergency Use Approval (EUA) from the Medicines and Healthcare products Regulatory Agency (MHRA) on December 2, 2020, is currently the leading prophylactic vaccine with 2021 sales of $41.5
PM360
SEPTEMBER 21, 2023
Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.
European Pharmaceutical Review
NOVEMBER 28, 2024
Without sufficient support systems and experienced reviewers, the implementation timelines were extended, with final compliance dates now pushed to December 2028 (from May 2024 originally). This situation raises concerns that similar delays could impact the EU AI Act, creating uncertainty for companies relying on clear, consistent timelines.
Expert insights. Personalized for you.
98 
Let's personalize your content